Initial viral response is the most powerful predictor of the emergence of YMDD mutant virus in chronic hepatitis B patients treated with lamivudine

Aim:  Lamivudine (LAM) has been widely used to treat chronic hepatitis B (CHB) patients, but the emergence of a LAM‐resistant virus greatly limits its therapeutic efficacy. In this study, we tried to identify factors affecting the emergence of a LAM‐resistant virus in CHB patients treated with LAM.

[1]  D. Snydman.  Entecavir versus Lamivudine for Patients with HBeAg-Negative Chronic Hepatitis BLai C-L, for the BEHoLD AI463027 Study Group (Queen Mary Hosp, Hong Kong; et al) N Engl J Med 354:1011–1020, 2006§ , 2007 .

[2]  D. Snydman.  A Comparison of Entecavir and Lamivudine for HBeAg-Positive Chronic Hepatitis B , 2007 .

[3]  C. Mazzucco,et al.  Two-Year Assessment of Entecavir Resistance in Lamivudine-Refractory Hepatitis B Virus Patients Reveals Different Clinical Outcomes Depending on the Resistance Substitutions Present , 2006, Antimicrobial Agents and Chemotherapy.

[4]  George Kitis,et al.  Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. , 2006, Gastroenterology.

[5]  C. Mazzucco,et al.  Entecavir resistance is rare in nucleoside naïve patients with hepatitis B , 2006, Hepatology.

[6]  A. Cross,et al.  Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. , 2006, Gastroenterology.

[7]  Ching-Lung Lai,et al.  Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. , 2006, The New England journal of medicine.

[8]  George Kitis,et al.  Outcome of hepatitis B e antigen–negative chronic hepatitis B on long‐term nucleos(t)ide analog therapy starting with lamivudine , 2005, Hepatology.

[9]  Y. Liaw,et al.  Virus and transaminase levels determine the emergence of drug resistance during long-term lamivudine therapy in chronic hepatitis B. , 2005, Journal of hepatology.

[10]  H. Nomura,et al.  Body surface area is an independent factor contributing to the effects of lamivudine treatment. , 2005, Hepatology research : the official journal of the Japan Society of Hepatology.

[11]  T. Berg,et al.  Comparison of adefovir and tenofovir in the treatment of lamivudine‐resistant hepatitis B virus infection , 2004, Hepatology.

[12]  Oliver N Keene,et al.  Lamivudine for patients with chronic hepatitis B and advanced liver disease. , 2004, The New England journal of medicine.

[13]  Yoshiyuki Suzuki,et al.  Severe acute exacerbation of liver disease may reduce or delay emergence of YMDD motif mutants in long‐term lamivudine therapy for hepatitis B e antigen‐positive chronic hepatitis B , 2004, Journal of medical virology.

[14]  D. Lavanchy,et al.  Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures , 2004, Journal of viral hepatitis.

[15]  J. Tsai,et al.  Clinical evaluation of the COBAS Amplicor HBV monitor test for measuring serum HBV DNA and comparison with the Quantiplex branched DNA signal amplification assay in Taiwan , 2004, Journal of Clinical Pathology.

[16]  Ching-Lung Lai,et al.  Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[17]  M. Wulfsohn,et al.  Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. , 2003, The New England journal of medicine.

[18]  M. Wulfsohn,et al.  Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. , 2003, The New England journal of medicine.

[19]  M. Yuen,et al.  Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy , 2001, Hepatology.

[20]  K. Tanikawa,et al.  Development of a new method for detecting a mutation in the gene encoding hepatitis B virus reverse transcriptase active site (YMDD motif) , 2000 .

[21]  C. Chu,et al.  Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy , 1999, Hepatology.

[22]  Shiro Iino,et al.  Quantitative Detection of Hepatitis B Virus by Transcription-Mediated Amplification and Hybridization Protection Assay , 1999, Journal of Clinical Microbiology.

[23]  N. Leung,et al.  A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. , 1998, The New England journal of medicine.

[24]  K. Walters,et al.  Identification and characterization of mutations in hepatitis B virus resistant to lamivudine , 1998 .